Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shuttle Pharmaceuticals Holdings, Inc. files regulatory reports that document its clinical-stage pharmaceutical business, Molecule.ai software platform, capital structure and governance. Registration statements and related amendments describe securities offered by the company, risk factors, use-of-proceeds disclosures and security terms, including common stock and pre-funded warrant structures.
Its 8-K reports record material agreements, public-offering activity, preliminary operating results and executive or consulting arrangements. Proxy materials cover annual meeting matters such as director elections, auditor ratification, executive-compensation votes and charter-authority proposals.
Joseph Tung, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and the award was recorded at $0. The RSUs vest in three equal installments, with one-third vesting on each of 08/08/2026, 08/08/2027 and 08/08/2028, and the reported ownership form is direct. Following this reported transaction, the RSUs correspond to 29,240 underlying shares.
The filing discloses an equity award that aligns a director with shareholder interests via long-term vesting, but it does not provide the company’s total outstanding share count or other compensation terms needed to assess dilution or material financial impact.
Timothy J. Lorber, Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), was granted a total of 54,094 restricted stock units (RSUs) in transactions dated 08/08/2025. Each RSU represents a contingent right to receive one share of common stock and the grants were reported on a Section 16 Form 4.
The awards are split into two grants: 29,240 RSUs that vest one-third on each of 08/08/2026, 08/08/2027 and 08/08/2028, and 24,854 RSUs that vest on 02/08/2026. Both grants show an acquisition price of $0 and are held in a direct ownership form.
Shuttle Pharmaceuticals (SHPH) reported continued development-stage operations with no revenue and a six-month net loss of $6,759,472. Cash and cash equivalents rose to $4,817,672 at June 30, 2025 from $1,920,144 at year-end 2024, driven by net financing proceeds of approximately $8.78 million. Total assets were $5.50 million and stockholders' equity increased to $3.61 million as shares outstanding expanded to 1,070,773.
The company disclosed a substantial doubt about its ability to continue as a going concern: management states existing cash, equity proceeds and an undrawn $2.0 million revolving note are not expected to fund operations and clinical trials through the next 12 months. Material items include reverse stock splits to meet Nasdaq requirements, equity financings in March and June 2025, accelerated stock-based compensation of about $0.5 million from RSU modifications, and a $2.0 million payment to an IR agency recorded as expense.
Shuttle Pharmaceuticals Holdings has filed a Form D notice for an exempt securities offering under Rule 506(b). The company has successfully raised $4,250,000 through the offering, which was completed on June 20, 2025, with no remaining amount to be sold.
Key details of the offering:
- Securities offered include equity, options/warrants, and securities to be acquired upon exercise
- WestPark Capital served as broker-dealer with sales commissions of $170,000
- Total of 1 investor participated in the offering
- Offering not intended to last more than one year
The company's leadership includes Christopher Cooper (CEO), Peter Dritschilo (President/COO), Mira Jung (Chief Scientific Officer), Tyvin Rich (Chief Medical Officer), and Timothy Lorber (CFO). The pharmaceutical company is headquartered in Gaithersburg, Maryland, and was incorporated in Delaware over five years ago.
Shuttle Pharmaceuticals Holdings (NASDAQ:SHPH) has entered into a private placement agreement with an accredited investor on June 20, 2025. The company will sell 21,924 shares of common stock at $3.60 per share and 1,158,953 pre-funded warrants at $3.599 per warrant with a $0.001 exercise price.
The agreement includes a registration rights requirement to file within 10 days and achieve effectiveness within 90-120 days. The company and insiders agreed to a 60-day lock-up period. WestPark Capital served as placement agent, receiving a 4% fee of gross proceeds plus expense reimbursement.